| Dihydroergotamine |
FDA approved |
Phase 1/2/3 completed |
Acute treatment of migraine with or without aura |
| Tegaserod |
FDA approved |
Phase 1/2/3 completed |
Treating irritable bowel syndrome with constipation |
| Ondansetron |
FDA approved |
Phase 1/2/3 completed |
Preventing nausea and vomiting during chemotherapy |
| Dolasetron |
FDA approved |
Phase 1/2/3 completed |
Preventing nausea and vomiting during chemotherapy |
| Tropisetron |
FDA approved |
Phase 1/2/3 completed |
Preventing nausea and vomiting induced by cytotoxic therapy and postoperative |
| Vilazodone |
FDA approved |
Phase 1/2/3 completed |
Treatment of major depressive disorder |
| Triptans |
FDA approved |
Phase 1/2/3 completed |
Treatment of migraine headache |
| Alosetron |
FDA approved |
Phase 1/2/3 completed |
Treatment of diarrhea-predominant irritable bowel syndrome (IBS) in women |
| Methysergide |
FDA approved |
No available data |
Treatment of vascular headache |
| Dihydroergocornine |
FDA approved |
No available data |
Treatment of symptoms of an idiopathic decline in mental capacity unrelated to a potentially reversible condition and age-related cognitive impairment |
| Indomethacin |
FDA approved |
Phase ½/3 completed |
Managing moderate to severe rheumatoid arthritis |
| Acemetacin |
UK approved |
Phase ½/3 completed |
Managing moderate to severe rheumatoid arthritis |
| Etodolac |
FDA approved |
Phase ½/3 completed |
Management of symptoms of osteoarthritis and rheumatoid arthritis, as well as pain |
| Carprofen |
FDA approved |
No available data |
Treating joint pain and post-surgical pain |
| Cabergoline |
FDA approved |
Phase 1/2/3 completed |
Treating hyperprolactinemic disorders |
| Lisuride |
FDA approved |
Phase 1/2/3 completed |
Anti-Parkinson's drug |
| Bromocriptine |
FDA approved |
Phase 1/2/3 completed |
Treating galactorrhea due to hyperprolactinemia and other prolactin-related conditions and early Parkinsonian syndrome |
| Methylergometrine |
FDA approved |
Phase 1/2/3 completed |
Preventing and controling uterine atony and hemorrhage |
| Sertindole |
FDA approved |
Phase 1/2/3 completed |
Treating schizophrenia |
| Pindolol |
FDA approved |
Phase 1/2/3 completed |
Treating hypertension, edema, ventricular tachycardias, and atrial fibrillation |
| Carvedilol |
FDA approved |
Phase 1/2/3 completed |
Treating mild to severe heart failure and left ventricular dysfunction after myocardial infarction |
| Nicergoline |
FDA approved |
Phase 1/2/3 completed |
Treating symptoms associated with cerebrovascular abnormalities |
| Dihydroergocristine |
FDA approved |
No available data |
Delaying progressive mental decline in conditions like Alzheimer's disease |
| Ergometrine |
FDA approved |
Phase 1/2/3 completed |
Treating postpartum hemorrhage and post abortion hemorrhage in patients with uterine atony |
| Yohimbine |
FDA approved |
Phase 1/2/3 completed |
Treating impotence |
| Vinblastine |
FDA approved |
Phase 1/2/3 completed |
Treating breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma |
| Vinorelbine |
FDA approved |
Phase 1/2/3 completed |
Treating metastatic non-small cell lung carcinoma (NSLC) |
| Vindesine |
FDA approved |
Phase 1/2/3 completed |
Treating mainly acute lymphocytic leukemia |
| Vinflunine |
FDA approved |
Phase 1/2/3 completed |
Treating transitional cell carcinoma of the urothelial tract |
| Tadalafil |
FDA approved |
Phase 1/2/3 completed |
Treating erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension |
| Melatonin |
FDA approved |
Phase 1/2/3 completed |
Treating jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind and benzodiazepine and nicotine withdrawal |
| Alectinib |
FDA approved |
Phase 1/2/3 completed |
Treating anaplastic lymphoma kinase positive metastatic non-small cell lung cancer |
| Tezacaftor |
FDA approved |
Phase 1/2/3 completed |
Treating homozygous or heterozygous F508del mutation cystic fibrosis |
| Panobinostat |
FDA approved |
Phase 1/2/3 completed |
Treating multiple myeloma |
| Bazedoxifene |
FDA approved |
Phase 1/2/3 completed |
Treating moderate to severe vasomotor symptoms in menopause and osteoporosis |
| Osimertinib |
FDA approved |
Phase 1/2 completed |
Treating certain types of non-small cell lung carcinoma |
| Phase 3: active |
| Rucaparib |
FDA approved |
Phase 1/2 completed |
Treating recurrent ovarian and prostate cancers in previously treated adults |
| Phase 3: active |
| Arbidol |
NMPA approved |
Phase 1/2/3 completed |
Treatment and prophylaxis of influenza and other respiratory viruses |
| Fluvastatin |
FDA approved |
Phase 1/2/3 completed |
Lowering lipid levels and reducing the risk of cardiovascular disease |
| Delavirdine |
FDA approved |
Phase 1/2/3 completed |
Treating HIV infection |
| Midostaurin |
FDA approved |
Phase 1/2 completed |
Treating high-risk acute myeloid leukemia with specific mutations, aggressive systemic mastocytosis, systemic mastocytosis with associated hematologic neoplasm, or mast cell leukemia |
| Phase 3: active |
| Zafirlukast |
FDA approved |
Phase 1 completed |
Prophylaxis and chronic treatment of asthma |
| Phase 2/3: active |
| Reserpine |
FDA approved |
Phase 1/2/3 completed |
Treating hypertension |
| Metergoline |
FDA approved |
No available data |
Treating seasonal affective disorder, prolactin hormone regulation |
| Lurbinectedin |
FDA approved |
Phase 1/2/3 completed |
Treating metastatic small-cell lung cancer |
